Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Sales115153230253252280
EBITDA33,656,5118120120151
Operating profit (EBIT)32,555,910755,2100120
Pre-Tax Profit (EBT)------
Net income13,133,418,5-15351,772,8
P/E ratio49,223,732,3-7,5219,814,3
EPS ( $ )0,290,730,42-2,130,811,12
Dividend per Share ( $ )------
Yield------
Reference price ( $ )14.2817.2913.55161616
Announcement Date03/04/2015
11:30am
03/08/2016
11:30am
03/08/2017
11:31am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201420152016201720182019
Debt-14492,226215566,7
Finance45,8-----
Operating income (EBITDA)33,656,5118120120151
Leverage
(Debt/EBITDA)
-2,55x0,78x2,17x1,29x0,44x
Capital Expenditure0,073,561,232,572,562,32
Book Value Per Share (BVPS)1,85 $1,90 $3,85 $0,75 $1,94 $3,63 $
Cash Flow per Share0,69 $0,41 $0,19 $1,35 $1,37 $1,91 $
Announcement Date03/04/2015
11:30am
03/08/2016
11:30am
03/08/2017
11:31am
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2017e 2018e
Capitalization 746 M$ -
Entreprise Value (EV) 1 008 M$ 901 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 19,8x
Capitalization / Revenue 2,95x 2,96x
EV / Revenue 3,99x 3,58x
EV / EBITDA 8,38x 7,51x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 21,5x 8,25x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 21,8% 39,9%
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) -60,6% 20,5%
ROA (Net Profit / Asset) 20,9% -
ROE (Net Profit / Equities) 52,7% 99,7%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   1,02% 1,02%
Cash Flow / Sales 24,8% 25,3%
Capital Intensity (Assets / Sales) -2,90x -
Financial Leverage (Net Debt / EBITDA) 2,17x 1,29x
EPS & Dividend